Chatham Capital Group Inc. Sells 2,340 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Chatham Capital Group Inc. cut its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 3.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 61,105 shares of the exchange traded fund’s stock after selling 2,340 shares during the period. SPDR S&P Biotech ETF makes up approximately 1.4% of Chatham Capital Group Inc.’s investment portfolio, making the stock its 23rd largest holding. Chatham Capital Group Inc. owned about 0.12% of SPDR S&P Biotech ETF worth $5,532,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of XBI. Gradient Investments LLC acquired a new position in SPDR S&P Biotech ETF during the 1st quarter valued at about $27,000. Cranbrook Wealth Management LLC bought a new position in shares of SPDR S&P Biotech ETF during the 4th quarter worth approximately $26,000. Quattro Financial Advisors LLC lifted its position in shares of SPDR S&P Biotech ETF by 49.6% during the 4th quarter. Quattro Financial Advisors LLC now owns 374 shares of the exchange traded fund’s stock worth $31,000 after buying an additional 124 shares in the last quarter. Lehman & Derafelo Financial Resources LLC bought a new position in shares of SPDR S&P Biotech ETF during the 4th quarter worth approximately $32,000. Finally, Asset Dedication LLC bought a new position in shares of SPDR S&P Biotech ETF during the 1st quarter worth approximately $41,000.

Shares of SPDR S&P Biotech ETF stock traded down $1.53 during mid-day trading on Friday, hitting $81.49. 3,080,500 shares of the stock were exchanged, compared to its average volume of 4,897,564. SPDR S&P Biotech ETF has a 12 month low of $64.38 and a 12 month high of $101.55.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Rockland Register and is the sole property of of Rockland Register. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://rocklandregister.com/2019/06/14/chatham-capital-group-inc-has-5-53-million-holdings-in-spdr-sp-biotech-etf-xbi.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: No Load Funds

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.